EUCTR2006-005562-39-FR进行中(未招募)不适用
ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML) - ALFA 0703
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Aged of 65 to 79 years
- •- With a morphologically proven diagnosis of AML according to WHO classification either de novo or post -MDS
- •- Not previously treated for AML
- •- Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- APL in the WHO classification.
- •- Ph1-positive AML or prior Ph1-positive disease
- •- AML evolving from a prior MPS in the WHO classification.
- •- Prior treatment with chemotherapy or radiotherapy for another tumor
- •- Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
- •- Prior advanced malignant hepatic tumor
- •- ECOG Performance Status Score > 2.
- •- Known Poor-risk cytogenetics, including monosomy 7, abnormalities of both chromosomes 5 and 7, 3q abnormality, and complex karyotype (5 anomalies or more).
- •- Creatinine level more than 2x's the upper limit of the normal range (ULN) at the laboratory where the analysis was performed, except if AML-related.
- •- Total serum bilirubin more than 2x's the ULN at the laboratory where the analysis was - performed, except if AML-related.
- •- AST (SGOT) or ALT (SGPT) more than 2.5x's the ULN at the laboratory where the analysis was performed, except if AML-related
- •- LVEF less than.55 or equivalent by doppler echocardiography
- •- Known intolerance to Azacitidine, mannitol, retinoids, pegfilgrastim
- •- Positive serum test for HIV and HTLV-1
- •- NYHA Grade 3/4 cardiac disease .
- •- Severe infection at inclusion time
- •- Psychiatric disease or an history of non-compliance to medical regimens or patients considered potentially unreliable.
- •- Absence of health care insurance (affiliation à un régime de Sécurité Sociale)
- •- Participation to any study requiring informed consent
研究者
相似试验
已完成
不适用
A RANDOMIZED ,3 ARM, MULTICENTRE, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF T-DM1 COMBINED WITH PERTUZUMAD OR T-DM1 COMBINED WITH PERTUZUMAB-PLACEBO (BLINDED FOR PERTUZUMAB) VERSUS THE COMBINATION OF TRANSTUZUMAB PLUS TAXANE, AS FIRST LINE TREATMENT IN HER2-POSITIVE PROGRESSIVE OR RECURRENT LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC)PER-084-10F. HOFFMANN-LA ROCHE LTD.,20
已完成
3 期
A study on treatment of COVID-19 patients with study drug along with standard of careCTRI/2020/05/025369Medanta Institute of Education and Research MIER180
进行中(未招募)
1 期
A Study of Atezolizumab Versus Placebo Given with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III/IV Ovarian, Fallopian Tube, Or Primary Peritoneal CancerEUCTR2016-003472-52-NOF. Hoffman-La Roche Ltd.1,301
进行中(未招募)
1 期
A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial.CTIS2023-508156-20-00Vaestra Goetalandsregionen40
已完成
4 期
Comparison of WallFlex Biliary Fully Covered metal stents to plastic stents in patients with Chronic PancreatitisCTRI/2012/11/003103Boston Scientific40
